Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2011

Open Access 01-12-2011 | Research

Effects of 1α,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells

Authors: Wei-Lin W Wang, Namita Chatterjee, Sridar V Chittur, JoEllen Welsh, Martin P Tenniswood

Published in: Molecular Cancer | Issue 1/2011

Login to get access

Abstract

Background

There is evidence from epidemiological and in vitro studies that the biological effects of testosterone (T) on cell cycle and survival are modulated by 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) in prostate cancer. To investigate the cross talk between androgen- and vitamin D-mediated intracellular signaling pathways, the individual and combined effects of T and 1,25(OH)2D3 on global gene expression in LNCaP prostate cancer cells were assessed.

Results

Stringent statistical analysis identifies a cohort of genes that lack one or both androgen response elements (AREs) or vitamin D response elements (VDREs) in their promoters, which are nevertheless differentially regulated by both steroids (either additively or synergistically). This suggests that mechanisms in addition to VDR- and AR-mediated transcription are responsible for the modulation of gene expression. Microarray analysis shows that fifteen miRNAs are also differentially regulated by 1,25(OH)2D3 and T. Among these miR-22, miR-29ab, miR-134, miR-1207-5p and miR-371-5p are up regulated, while miR-17 and miR-20a, members of the miR-17/92 cluster are down regulated. A number of genes implicated in cell cycle progression, lipid synthesis and accumulation and calcium homeostasis are among the mRNA targets of these miRNAs. Thus, in addition to their well characterized effects on transcription, mediated by either or both cognate nuclear receptors, 1,25(OH)2D3 and T regulate the steady state mRNA levels by modulating miRNA-mediated mRNA degradation, generating attenuation feedback loops that result in global changes in mRNA and protein levels. Changes in genes involved in calcium homeostasis may have specific clinical importance since the second messenger Ca2+ is known to modulate various cellular processes, including cell proliferation, cell death and cell motility, which affects prostate cancer tumor progression and responsiveness to therapy.

Conclusions

These data indicate that these two hormones combine to drive a differentiated phenotype, and reinforce the idea that the age dependent decline in both hormones results in the de-differentiation of prostate tumor cells, which results in increased proliferation, motility and invasion common to aggressive tumors. These studies also reinforce the potential importance of miRNAs in prostate cancer progression and therapeutic outcomes.
Appendix
Available only for authorised users
Literature
1.
2.
3.
Vis AN, Schroder FH: Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways. BJU Int. 2009, 104: 438-448. 10.1111/j.1464-410X.2009.08695.xCrossRefPubMed
4.
Vis AN, Schroder FH: Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5alpha-reductase. BJU Int. 2009, 104: 1191-1197. 10.1111/j.1464-410X.2009.08743.xCrossRefPubMed
5.
Giovannucci E: Expanding roles of vitamin D. J Clin Endocrinol Metab. 2009, 94: 418-420. 10.1210/jc.2008-2695CrossRefPubMed
6.
Thorne J, Campbell MJ: The vitamin D receptor in cancer. Proc Nutr Soc. 2008, 67: 115-127. 10.1017/S0029665108006964CrossRefPubMed
7.
Garland CF, Gorham ED, Mohr SB, Garland FC: Vitamin D for cancer prevention: global perspective. Ann Epidemiol. 2009, 19: 468-483. 10.1016/j.annepidem.2009.03.021CrossRefPubMed
8.
Schwartz GG, Skinner HG: Vitamin D status and cancer: new insights. Curr Opin Clin Nutr Metab Care. 2007, 10: 6-11.PubMed
9.
Tseng M, Breslow RA, DeVellis RF, Ziegler RG: Dietary patterns and prostate cancer risk in the National Health and Nutrition Examination Survey Epidemiological Follow-up Study cohort. Cancer Epidemiol Biomarkers Prev. 2004, 13: 71-77. 10.1158/1055-9965.EPI-03-0076CrossRefPubMed
10.
Barnett CM, Nielson CM, Shannon J, Chan JM, Shikany JM, Bauer DC: Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men. Cancer Causes Control. 2010, 21: 1297-1303. 10.1007/s10552-010-9557-yPubMedCentralCrossRefPubMed
11.
Park SY, Cooney RV, Wilkens LR, Murphy SP, Henderson BE, Kolonel LN: Plasma 25-hydroxyvitamin D and prostate cancer risk: the multiethnic cohort. Eur J Cancer. 2010, 46: 932-936. 10.1016/j.ejca.2009.12.030PubMedCentralCrossRefPubMed
12.
Rhee HV, Coebergh JW, Vries ED: Sunlight, vitamin D and the prevention of cancer: a systematic review of epidemiological studies. Eur J Cancer Prev. 2009
13.
Yin L, Raum E, Haug U, Arndt V, Brenner H: Meta-analysis of longitudinal studies: Serum vitamin D and prostate cancer risk. Cancer Epidemiol. 2009, 33: 435-445. 10.1016/j.canep.2009.10.014CrossRefPubMed
14.
Alagbala AA, Moser MT, Johnson CS, Trump DL, Foster BA: Characterization of Vitamin D insensitive prostate cancer cells. J Steroid Biochem Mol Biol. 2007, 103: 712-716. 10.1016/j.jsbmb.2006.12.008PubMedCentralCrossRefPubMed
15.
Banach-Petrosky W, Ouyang X, Gao H, Nader K, Ji Y, Suh N: Vitamin D inhibits the formation of prostatic intraepithelial neoplasia in Nkx3.1;Pten mutant mice. Clin Cancer Res. 2006, 12: 5895-5901. 10.1158/1078-0432.CCR-06-1039CrossRefPubMed
16.
Mordan-McCombs S, Brown T, Wang WL, Gaupel AC, Welsh J, Tenniswood M: Tumor progression in the LPB-Tag transgenic model of prostate cancer is altered by vitamin D receptor and serum testosterone status. J Steroid Biochem Mol Biol. 2010, 121: 368-371. 10.1016/j.jsbmb.2010.03.062PubMedCentralCrossRefPubMed
17.
Murthy S, Agoulnik IU, Weigel NL: Androgen receptor signaling and vitamin D receptor action in prostate cancer cells. Prostate. 2005, 64: 362-372. 10.1002/pros.20251CrossRefPubMed
18.
Oades GM, Dredge K, Kirby RS, Colston KW: Vitamin D receptor-dependent antitumour effects of 1, 25-dihydroxyvitamin D3 and two synthetic analogues in three in vivo models of prostate cancer. BJU Int. 2002, 90: 607-616. 10.1046/j.1464-410X.2002.02964.xCrossRefPubMed
19.
Saito T, Okamoto R, Haritunians T, O'Kelly J, Uskokovic M, Maehr H: Novel Gemini vitamin D(3) analogs have potent antitumor activity. J Steroid Biochem Mol Biol. 2008, 112: 151-156.PubMedCentralCrossRefPubMed
20.
Washington MN, Kim JS, Weigel NL: 1alpha, 25-dihydroxyvitamin D(3) inhibits C4-2 prostate cancer cell growth via a retinoblastoma protein (Rb)-independent G(1) arrest. Prostate. 2010
21.
Bao BY, Yao J, Lee YF: 1alpha, 25-dihydroxyvitamin D3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis. Carcinogenesis. 2006, 27: 1883-1893. 10.1093/carcin/bgl041CrossRefPubMed
22.
Ben Shoshan M, Amir S, Dang DT, Dang LH, Weisman Y, Mabjeesh NJ: 1alpha, 25-dihydroxyvitamin D3 (Calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells. Mol Cancer Ther. 2007, 6: 1433-1439. 10.1158/1535-7163.MCT-06-0677CrossRefPubMed
23.
Jiang F, Bao J, Li P, Nicosia SV, Bai W: Induction of ovarian cancer cell apoptosis by 1, 25-dihydroxyvitamin D3 through the down-regulation of telomerase. J Biol Chem. 2004, 279: 53213-53221. 10.1074/jbc.M410395200CrossRefPubMed
24.
Kizildag S, Ates H, Kizildag S: Treatment of K562 cells with 1, 25-dihydroxyvitamin D(3) induces distinct alterations in the expression of apoptosis-related genes BCL2, BAX, BCL(XL), and p21. Ann Hematol. 2009
25.
Mantell DJ, Owens PE, Bundred NJ, Mawer EB, Canfield AE: 1 alpha, 25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Res. 2000, 87: 214-220.CrossRefPubMed
26.
Campbell MJ, Koeffler HP: Toward therapeutic intervention of cancer by vitamin D compounds. J Natl Cancer Inst. 1997, 89: 182-185. 10.1093/jnci/89.3.182CrossRefPubMed
27.
Miller GJ, Stapleton GE, Hedlund TE, Moffat KA: Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1alpha, 25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines. Clin Cancer Res. 1995, 1: 997-1003.PubMed
28.
Zhuang SH, Burnstein KL: Antiproliferative effect of 1alpha, 25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology. 1998, 139: 1197-1207. 10.1210/en.139.3.1197PubMed
29.
Weigel NL: Interactions between vitamin D and androgen receptor signaling in prostate cancer cells. Nutr Rev. 2007, 65: S116-S117. 10.1301/nr.2007.aug.S116-S117CrossRefPubMed
30.
Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F: Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res. 2008, 68: 6162-6170. 10.1158/0008-5472.CAN-08-0144PubMedCentralCrossRefPubMed
31.
Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T: MicroRNA expression profiling in prostate cancer. Cancer Res. 2007, 67: 6130-6135. 10.1158/0008-5472.CAN-07-0533CrossRefPubMed
32.
Li T, Li D, Sha J, Sun P, Huang Y: MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells. Biochem Biophys Res Commun. 2009, 383: 280-285. 10.1016/j.bbrc.2009.03.077CrossRefPubMed
33.
Ribas J, Ni X, Haffner M, Wentzel EA, Salmasi AH, Chowdhury WH: miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res. 2009, 69: 7165-7169. 10.1158/0008-5472.CAN-09-1448PubMedCentralCrossRefPubMed
34.
Sun T, Yang M, Kantoff P, Lee GS: Role of microRNA-221/-222 in cancer development and progression. Cell Cycle. 2009, 8: 2315-2316. 10.4161/cc.8.15.9221CrossRefPubMed
35.
Shi XB, Xue L, Yang J, Ma AH, Zhao J, Xu M: An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc Natl Acad Sci USA. 2007, 104: 19983-19988. 10.1073/pnas.0706641104PubMedCentralCrossRefPubMed
36.
Shi XB, Xue L, Ma AH, Tepper CG, Kung HJ, White RW: miR-125b promotes growth of prostate cancer xenograft tumor through targeting pro-apoptotic genes. Prostate. 2011, 71: 538-549. 10.1002/pros.21270PubMedCentralCrossRefPubMed
37.
38.
Rokhlin OW, Scheinker VS, Taghiyev AF, Bumcrot D, Glover RA, Cohen MB: MicroRNA-34 mediates AR-dependent p53-induced apoptosis in prostate cancer. Cancer Biol Ther. 2008, 7: 1288-1296. 10.4161/cbt.7.8.6284CrossRefPubMed
39.
Thorne JL, Maguire O, Doig CL, Battaglia S, Fehr L, Sucheston LE: Epigenetic control of a VDR-governed feed-forward loop that regulates p21(waf1/cip1) expression and function in non-malignant prostate cells. Nucleic Acids Res. 2011, 39: 2045-2056. 10.1093/nar/gkq875PubMedCentralCrossRefPubMed
40.
Krishnan AV, Shinghal R, Raghavachari N, Brooks JD, Peehl DM, Feldman D: Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays. Prostate. 2004, 59: 243-251. 10.1002/pros.20006CrossRefPubMed
41.
Peehl DM, Shinghal R, Nonn L, Seto E, Krishnan AV, Brooks JD: Molecular activity of 1, 25-dihydroxyvitamin D3 in primary cultures of human prostatic epithelial cells revealed by cDNA microarray analysis. J Steroid Biochem Mol Biol. 2004, 92: 131-141. 10.1016/j.jsbmb.2004.07.003CrossRefPubMed
42.
Wang TT, Tavera-Mendoza LE, Laperriere D, Libby E, MacLeod NB, Nagai Y: Large-scale in silico and microarray-based identification of direct 1, 25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005, 19: 2685-2695. 10.1210/me.2005-0106CrossRefPubMed
43.
Mohri T, Nakajima M, Takagi S, Komagata S, Yokoi T: MicroRNA regulates human vitamin D receptor. Int J Cancer. 2009, 125: 1328-1333. 10.1002/ijc.24459CrossRefPubMed
44.
Wang WL, McHenry P, Jeffrey R, Schweitzer D, Helquist P, Tenniswood M: Effects of Iejimalide B, a marine macrolide, on growth and apoptosis in prostate cancer cell lines. J Cell Biochem. 2008, 105: 998-1007. 10.1002/jcb.21898CrossRefPubMed
45.
Colston KW, Hansen CM: Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer. Endocr Relat Cancer. 2002, 9: 45-59. 10.1677/erc.0.0090045CrossRefPubMed
46.
Harris DM, Go VL: Vitamin D and colon carcinogenesis. J Nutr. 2004, 134: 3463S-3471S.PubMed
47.
Welsh J, Wietzke JA, Zinser GM, Smyczek S, Romu S, Tribble E: Impact of the Vitamin D3 receptor on growth-regulatory pathways in mammary gland and breast cancer. J Steroid Biochem Mol Biol. 2002, 83: 85-92. 10.1016/S0960-0760(02)00277-7CrossRefPubMed
48.
Zhang X, Nicosia SV, Bai W: Vitamin D receptor is a novel drug target for ovarian cancer treatment. Curr Cancer Drug Targets. 2006, 6: 229-244. 10.2174/156800906776842939CrossRefPubMed
49.
Khan MT, Wagner L, Yule DI, Bhanumathy C, Joseph SK: Akt kinase phosphorylation of inositol 1, 4, 5-trisphosphate receptors. J Biol Chem. 2006, 281: 3731-3737.CrossRefPubMed
50.
Al Ansary D, Bogeski I, Disteldorf BM, Becherer U, Niemeyer BA: ATP modulates Ca2+ uptake by TRPV6 and is counteracted by isoform-specific phosphorylation. FASEB J. 2010, 24: 425-435. 10.1096/fj.09-141481CrossRefPubMed
51.
Tombal B, Denmeade SR, Gillis JM, Isaacs JT: A supramicromolar elevation of intracellular free calcium ([Ca(2+)](i)) is consistently required to induce the execution phase of apoptosis. Cell Death Differ. 2002, 9: 561-573. 10.1038/sj.cdd.4400999CrossRefPubMed
52.
Szabadkai G, Duchen MR: Mitochondria: the hub of cellular Ca2+ signaling. Physiology (Bethesda). 2008, 23: 84-94.CrossRef
53.
Sonkoly E, Wei T, Pavez LE, Suzuki H, Kato M, Torma H: Protein kinase C-dependent upregulation of miR-203 induces the differentiation of human keratinocytes. J Invest Dermatol. 2010, 130: 124-134. 10.1038/jid.2009.294CrossRefPubMed
54.
Vanden Abeele F, Skryma R, Shuba Y, Van Coppenolle F, Slomianny C, Roudbaraki M: Bcl-2-dependent modulation of Ca(2+) homeostasis and store-operated channels in prostate cancer cells. Cancer Cell. 2002, 1: 169-179. 10.1016/S1535-6108(02)00034-XCrossRefPubMed
55.
Flourakis M, Prevarskaya N: Insights into Ca2+ homeostasis of advanced prostate cancer cells. Biochim Biophys Acta. 2009, 1793: 1105-1109. 10.1016/j.bbamcr.2009.01.009CrossRefPubMed
56.
57.
Nakagawa K, Tsugawa N, Okamoto T, Kishi T, Ono T, Kubodera N: Rapid control of transmembrane calcium influx by 1alpha, 25-dihydroxyvitamin D3 and its analogues in rat osteoblast-like cells. Biol Pharm Bull. 1999, 22: 1058-1063.CrossRefPubMed
58.
Steinsapir J, Socci R, Reinach P: Effects of androgen on intracellular calcium of LNCaP cells. Biochem Biophys Res Commun. 1991, 179: 90-96. 10.1016/0006-291X(91)91338-DCrossRefPubMed
59.
Cheng HT, Chen JY, Huang YC, Chang HC, Hung WC: Functional role of VDR in the activation of p27Kip1 by the VDR/Sp1 complex. J Cell Biochem. 2006, 98: 1450-1456. 10.1002/jcb.20780CrossRefPubMed
60.
Huang YC, Hung WC: 1, 25-dihydroxyvitamin D3 transcriptionally represses p45Skp2 expression via the Sp1 sites in human prostate cancer cells. J Cell Physiol. 2006, 209: 363-369. 10.1002/jcp.20741CrossRefPubMed
61.
McGaffin KR, Chrysogelos SA: Identification and characterization of a response element in the EGFR promoter that mediates transcriptional repression by 1, 25-dihydroxyvitamin D3 in breast cancer cells. J Mol Endocrinol. 2005, 35: 117-133. 10.1677/jme.1.01813CrossRefPubMed
62.
Ribas J, Ni X, Haffner M, Wentzel EA, Salmasi AH, Chowdhury WH: miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res. 2009, 69: 7165-7169. 10.1158/0008-5472.CAN-09-1448PubMedCentralCrossRefPubMed
63.
Xiong J, Du Q, Liang Z: Tumor-suppressive microRNA-22 inhibits the transcription of E-box-containing c-Myc target genes by silencing c-Myc binding protein. Oncogene. 2010, 29: 4980-4988. 10.1038/onc.2010.241CrossRefPubMed
64.
Boominathan L: The tumor suppressors p53, p63, and p73 are regulators of microRNA processing complex. PLoS One. 2010, 5: e10615- 10.1371/journal.pone.0010615PubMedCentralCrossRefPubMed
65.
Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A, Lund AH: Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem. 2008, 283: 1026-1033.CrossRefPubMed
66.
Trump DL, Chadha MK, Sunga AY, Fakih MG, Ashraf U, Silliman CG: Vitamin D deficiency and insufficiency among patients with prostate cancer. BJU Int. 2009, 104: 909-914. 10.1111/j.1464-410X.2009.08531.xPubMedCentralCrossRefPubMed
67.
Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001, 25: 402-408. 10.1006/meth.2001.1262CrossRefPubMed
68.
Huang dW, Sherman BT, Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009, 4: 44-57.CrossRef
Metadata
Title
Effects of 1α,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells
Authors
Wei-Lin W Wang
Namita Chatterjee
Sridar V Chittur
JoEllen Welsh
Martin P Tenniswood
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2011
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-10-58

Other articles of this Issue 1/2011

Molecular Cancer 1/2011 Go to the issue

Research

Inhibition of angiogenesis and suppression of colorectal cancer metastatic to the liver using the Sleeping Beauty Transposon System

Research

Antitumour effects of single or combined monoclonal antibodies directed against membrane antigens expressed by human B cells leukaemia

Research

Differential contributory roles of nucleotide excision and homologous recombination repair for enhancing cisplatin sensitivity in human ovarian cancer cells

Research

The human RECQ1 helicase is highly expressed in glioblastoma and plays an important role in tumor cell proliferation

Research

Oncogenic functions of hMDMX in in vitro transformation of primary human fibroblasts and embryonic retinoblasts

Research

Identification of an epigenetic biomarker panel with high sensitivity and specificity for colorectal cancer and adenomas
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits